Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin liposome plus cisplatin as neoadjuvant chemotherapy for cervical cancer
ChiCTR2000040811Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2020
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegylated liposomal doxorubicin and cisplatin in Cervical Cancer (CC), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective Response Rate. Started Nov 2020; status: recruiting.
02
Drugs
pegylated liposomal doxorubicincisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000040811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040811.